Helix Opco, LLC was awarded a $10.88 million firm fixed price definitive contract by the Centers for Disease Control and Prevention (CDC) on September 17, 2021 to provide genomic sequencing services. The contract has a period of performance through May 14, 2022 and was issued without a set-aside designation. As a for-profit limited liability company located in San Mateo, California, Helix Opco will deliver the sequencing services from its place of performance in the same city. No major subcontractors were identified. The contract supports the CDC's COVID-19 tracking and research efforts through applied genomic analysis.
Generated 3/1/24, 10:00 AM